NEWS

HDAC inhibitor showed an overall response rate of 25.8% in a phase II trial.
July 17

Study shows GTF2I mutation differentiates non-aggressive from aggressive thymic epithelial tumors.
July 17

Software will help physicians make sense of data generated by genomic tests.
July 17

More than half of personalized medicine patents are in cancer.
July 17

PD-1 checkpoint inhibitor outperforms standard chemotherapy in melanoma.
July 10

Researchers detect 41% more invasive tumors with 3D technology than traditional imaging.
July 10

1
2
3
4
5
6

RESEARCH WATCH

Mutant IDH prevents hepatocyte differentiation and promotes tumorigenesis via HNF-4α inhibition.
July 17

Oncogene-induced metabolic reprogramming alters global histone acetylation during tumorigenesis.
July 17

Mutations in ERBB family receptors or downstream effectors are found in 37% of gallbladder carcinomas.
July 17

Phosphorylation of ERβ at Tyr36 is critical for its transcriptional and antitumor activities.
July 10

The COX-2–PGE2 pathway drives angiogenesis, tumor growth, and metastasis independent of VEGF.
July 10

The small GTPase RAB7 is a lineage-specific driver of melanoma that is regulated by MYC and SOX10.
July 10

1
2
3
4
5
6

NOTED THIS WEEK

July 17, 2014

Roche announced that its phase III study of cobimetinib met its primary endpoint. An investigational MEK inhibitor, cobimetinib used in combination with Roche’s BRAF inhibitor vemurafenib (Zelboraf) helped patients with previously untreated BRAF V600 mutation–positive advanced melanoma live significantly longer without their disease worsening compared with vemurafenib alone. The company said data will be presented at an upcoming medical meeting and submitted to the FDA for marketing approval.

The levonorgestrel-releasing intrauterine system, or progesterone-releasing IUD, may be associated with a higher-than-expected incidence of breast cancer, according to a study of 93,843 Finnish women ages 30 to 49 who used the device to treat heavy menstrual bleeding from 1994 to 2007. Published in Obstetrics and Gynecology, the study found that the device did not increase the risk of uterine, ovarian, pancreatic, or lung cancers, but the number of new breast cancer cases was 19% higher in women who used the device than in the general population.

MabVax Therapeutics, Inc., and Telik, Inc., finalized their merger, with MabVax becoming a wholly owned subsidiary of Telik. Located in Palo Alto, CA, Telik is a clinical-stage drug development company focused on discovering and developing small-molecule drugs for cancer. MabVax focuses on the development of vaccines and antibody-based therapies for cancer.

According to research published in the
Journal of Clinical Oncology, patients with colorectal cancer who had the highest levels of vitamin D in their blood were half as likely to die of the disease as those with the lowest levels. Researchers tested blood samples from nearly 1,600 patients following surgery and found that patients with large tumors that had not yet metastasized derived the greatest benefit.
The team now plans to conduct a study to determine whether taking vitamin D supplements in combination with chemotherapy can improve survival rates among patients with colorectal cancer.

The V Foundation for Cancer Research and Stand Up To Cancer will collaborate on grants for research scholars working within an emerging scientific field known as convergence, a model of
research meant to spur innovation in combatting cancer. Announced at the 2014 ESPYs, a sports awards ceremony televised on ESPN, the grants will support collaborative cancer research among different fields of study, such as engineering, physical sciences, and life sciences. Stand Up To Cancer is investing $4 million in the grants program.

The American Thoracic Society, American College of Chest Physicians, and other organizations in the Forum of International Respiratory Societies issued a position statement taking a
dim view of electronic cigarettes.
“As a precaution,” the statement reads, “electronic nicotine-delivery devices should be restricted or banned until more information about their safety is available. If they are allowed, they should be closely regulated as medicines or tobacco products.”

RESEARCH WATCH